
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):
September 10, 2012**

A.P. PHARMA, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

**123 Saginaw Drive
Redwood City, CA**
(Address of principal executive offices)

001-33221
(Commission
File Number)

94-2875566
(IRS Employer
Identification No.)

94063
(Zip Code)

Registrant's telephone number, including area code: (650) 366-2626

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 8.01 Other Events.

On September 10, 2012, A.P. Pharma, Inc. (the “Company”) announced the appointment of Thomas Pitler, Ph.D. as Vice President of Business Development.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Document Description</u>
99.1	Press Release issued on September 10, 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

A.P. PHARMA, INC.

Date: September 10, 2012

By: /s/ John B. Whelan

John B. Whelan

President and Chief Executive Officer

**For Immediate Release****A.P. Pharma Appoints Thomas Pitler, Ph.D. as Vice President of Business Development**

REDWOOD CITY, Calif. – September 10, 2012 – A.P. Pharma, Inc. (OTCBB: APPA) today announced the appointment of Thomas Pitler, Ph.D. as vice president of business development.

“Tom has extensive business development experience in establishing long-term collaborations around platform technologies,” said John B. Whelan, A.P. Pharma’s president and chief executive officer. “As we look toward the potential commercialization of APF530, we are focusing on opportunities that support not just the APF530 program but also programs emerging from our proprietary Biochronomer™ technology. We are thrilled to have Tom join us during this pivotal time and look forward to his contributions to the A.P. Pharma executive team.”

Most recently, Dr. Pitler was vice president of business development at Chimerix, where he was responsible for the company’s interactions with potential partners, leading the due diligence and negotiations process around the licensing of clinical stage programs, preclinical assets and underlying technology. Earlier, Dr. Pitler held the position of senior vice president, chief business and financial officer at Neurogen, Inc. (acquired by Ligand Pharmaceuticals). At Neurogen, Dr. Pitler established research and development collaborations with pharmaceuticals companies, including Merck and Aventis. Dr. Pitler was also a Research Assistant Professor at the University of Maryland School of Medicine and has held other academic positions. He received a B.A. in Biology and a Ph.D. in Physiology from Wake Forest University.

About A.P. Pharma

A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company’s lead product, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. A.P. Pharma received a Complete Response Letter to its APF530 New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration in September 2012. For further information, please visit the Company’s web site at www.appharma.com.

Forward-looking Statements

This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks

- more -

and uncertainties, including uncertainties associated with the potential approval of APF530 and the potential timing for such approval, if approved at all, as well as risks relating to capital resources and liquidity, satisfactory completion of clinical studies, progress in research and development programs, launch and acceptance of new products and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law.

Contacts

Investor Relations Contact:

Michael Rice
Office Phone: (646) 597-6979
Email: mrice@lifesciadvisors.com

and

Corporate Contact:

John B. Whelan, President and Chief Executive Officer
Office Phone: 650-366-2626

###